These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33247603)

  • 21. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
    Aristieta A; Ruiz-Ortega JA; Morera-Herreras T; Miguelez C; Ugedo L
    Exp Neurol; 2019 Dec; 322():113036. PubMed ID: 31425688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fenobam modulates distinct electrophysiological mechanisms for regulating excessive gamma oscillations in the striatum of dyskinetic rats.
    Wang P; Dai W; Liu H; Liu H; Xu Y
    Exp Neurol; 2024 Aug; 378():114833. PubMed ID: 38782350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Thornton E; Hassall MM; Corrigan F; Vink R
    Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
    Tronci E; Francardo V
    J Neural Transm (Vienna); 2018 Aug; 125(8):1137-1144. PubMed ID: 29242978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AMPK-mediated autophagy pathway activation promotes ΔFosB degradation to improve levodopa-induced dyskinesia.
    Liu K; Zhang Z; Xu Y; Wu Y; Lian P; Ma Z; Tang Z; Zhang X; Yang X; Zhai H; Zhang L; Xu Y; Cao X
    Cell Signal; 2024 Jun; 118():111125. PubMed ID: 38432574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
    Nascimento GC; Bariotto-Dos-Santos K; Leite-Panissi CRA; Del-Bel EA; Bortolanza M
    Neurotox Res; 2018 Nov; 34(4):799-807. PubMed ID: 29611150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
    Ndlovu BC; Daniels WM; Mabandla MV
    Neurotox Res; 2016 Jan; 29(1):126-34. PubMed ID: 26459303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
    Lindenbach D; Conti MM; Ostock CY; Dupre KB; Bishop C
    Neuroscience; 2015 Dec; 310():12-26. PubMed ID: 26363150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Aguiar AS; Moreira EL; Hoeller AA; Oliveira PA; Córdova FM; Glaser V; Walz R; Cunha RA; Leal RB; Latini A; Prediger RD
    Neuroscience; 2013 Jul; 243():46-53. PubMed ID: 23558088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
    BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noradrenergic drugs for levodopa-induced dyskinesia.
    Colosimo C; Craus A
    Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of mGlu
    Frouni I; Hamadjida A; Kwan C; Bédard D; Nafade V; Gaudette F; Nuara SG; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2019 Nov; 158():107725. PubMed ID: 31351976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.